Specifically, PDGFRα and PDGF-CC have been recently associated with the triple-negative breast cancer (TNBC) subtype, while the PDGF signaling network seems particularly promising for targeted therapies for this breast cancer molecular subtype [8,11]. This evidence concerns the gene CXCR1 and breast carcinoma.